Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Cancer Immunol Res. 2019 Oct;7(10):1700-1713. doi: 10.1158/2326-6066.CIR-18-0725. Epub 2019 Aug 6.
Cancer Immunol Res. 2019.
PMID: 31387897
Free article.